As per MRFR analysis, the India Insulin Biosimilars Market Size was estimated at 26.12 (USD Million) in 2024.The India Insulin Biosimilars Market Industry is expected to grow from 45(USD Million) in 2025 to 300 (USD Million) by 2035. The India Insulin Biosimilars Market CAGR (growth rate) is expected to be around 18.823% during the forecast period (2025 - 2035).
The India insulin biosimilars market is witnessing significant growth driven by several key market drivers. One of the primary factors is the increasing prevalence of diabetes in the country, as India accounts for a considerable portion of the global diabetic population. The Indian government's initiatives to improve healthcare access and affordability have also spurred demand for insulin biosimilars, making treatments more accessible to patients.
Furthermore, rising healthcare costs have prompted both consumers and healthcare providers to seek cost-effective alternatives, positioning biosimilars as a more economical option compared to traditional insulin products.In recent times, the focus on enhancing pharmaceutical manufacturing capabilities in India has opened doors for both domestic and international players.
The government’s push for 'Make in India' underlines the importance of local production, which presents opportunities to explore the development of biosimilars that meet international regulatory standards. The increasing acceptance of biosimilars among healthcare professionals and patients is further bolstered by education and awareness campaigns about their safety and efficacy. Moreover, the rapid advancements in biotechnology and regulatory frameworks that support expedited approvals for biosimilars have led to a vibrant market landscape.
The advent of innovative delivery methods, such as pen devices and needle-free systems, is also creating new avenues for growth. With the surge in interest and investment in the biotech sector, alongside favorable government initiatives, there are ample opportunities to capture in the Indian insulin biosimilars market. This dynamic environment suggests that the sector will continue evolving, aligning its offerings with patient needs and healthcare system improvements in India.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The India Insulin Biosimilars Market Industry is witnessing significant growth due to the increasing number of diabetes cases in the country. According to the Indian Council of Medical Research, India has over 77 million individuals diagnosed with diabetes, and this number is projected to reach 134 million by 2045. As diabetes becomes more prevalent, the demand for insulin and its biosimilars will rise, establishing biosimilars as a crucial segment in diabetes management.
The growing awareness and acceptance of biosimilar insulin by healthcare professionals and patients are expected to further propel the market. Leading organizations like the Indian Diabetes Association are actively promoting the efficient management of diabetes, thus aiding the adoption of insulin biosimilars in pharmaceutical practices.
One of the primary drivers for the growth of the India Insulin Biosimilars Market Industry is the cost-effectiveness of biosimilar products compared to their originator biologics. The Government of India has introduced policies aimed at promoting the use of biosimilars to ensure affordable healthcare. With the average cost of insulin biosimilars being approximately 30-40% lower than branded insulins, patients are more inclined to opt for these alternatives.
This pricing strategy not only supports patient access but also enhances competition in the pharmaceutical market, thereby fostering innovation. Organizations such as the Association of Pharmaceutical Manufacturers of India have reported a surge in the number of biosimilar approvals, reflecting the industry's shift towards more economically sustainable treatment options.
The Indian government's push towards the production and use of biosimilars is a critical driver in the growth of the India Insulin Biosimilars Market Industry. The National Biotechnology Development Strategy aims to enhance the biotechnology sector and increase the accessibility of biologics and biosimilars. With biosimilars expected to capture 30-40% of the market share, the government is facilitating smooth regulatory pathways and incentivizing Research and Development (R&D) to boost domestic production.
The Central Drug Standard Control Organization is pursuing the rationalization of the workflows concerning the approval of biosimilars. This is expected to help the firms that are focusing on insulin biosimilar products. These policies are not merely supportive of growth, but also enhance the image of India as a biopharmaceutical manufacturing hub.
There is a growing awareness among healthcare providers and consumers regarding the benefits and safety profiles of biosimilars, which is positively impacting the India Insulin Biosimilars Market Industry. According to a survey conducted by the Ministry of Health and Family Welfare, more than 70% of healthcare professionals now have at least basic knowledge of biosimilars, indicating an increase in acceptance.
Furthermore, public health campaigns emphasizing the reliability and efficacy of biosimilars are helping to reshape perceptions and encourage physicians to prescribe these alternatives.Organizations like the Diabetes Foundation, India, are actively involved in educating patients about the various insulin options available, thus driving the adoption and utilization of insulin biosimilars across the nation.
The India Insulin Biosimilars Market encompasses a diverse range of types, reflecting the complex needs of diabetes management in the country. Rapid-acting biosimilars are particularly noteworthy as they provide patients with the ability to control postprandial blood sugar levels effectively, thus supporting better glycemic control. This segment captures a significant share, driven by the increasing prevalence of Type 2 diabetes, which is fueled by lifestyle changes, urbanization, and rising obesity rates.
Long-acting biosimilars also hold a prominent position in the market, offering patients convenience by minimizing the frequency of injections while maintaining stable insulin levels throughout the day. The demand for these formulations is rising, especially as healthcare providers emphasize the importance of consistent glycemic control to prevent long-term complications associated with diabetes.
Meanwhile, premixed biosimilars combine different types of insulin, catering to patients who may benefit from a more simplified dosing regimen. This segment has been gaining traction due to its user-friendly approach, which appeals to both patients and healthcare practitioners aiming for optimal therapeutic outcomes. The growth of each of these categories is supported by advancements in biotechnology, as well as an increase in public health initiatives recognizing the importance of insulin therapy in diabetes management.
However, the overall acceptance of biosimilars hinges on healthcare professionals' education about their efficacy and safety, as well as the need for regulatory updates and pricing strategies that can enhance affordability. The India Insulin Biosimilars Market continues to evolve, bolstered by these influential segments, which reflect the broader trends of personalization in treatment and the increasing focus on diabetes care management.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The India Insulin Biosimilars Market focuses significantly on the Indication segment, which consists mainly of Type I Diabetes and Type II Diabetes. Type I Diabetes, characterized by insulin deficiency, often necessitates lifelong insulin therapy, making it a crucial area for biosimilar development. In contrast, Type II Diabetes, linked to insulin resistance and often more prevalent in the adult population, also drives demand for more affordable insulin options.
With the growing prevalence of diabetes in India, influenced by lifestyle changes and dietary habits, the need for effective insulin treatments is rising, thereby boosting the India Insulin Biosimilars Market growth.The government of India has initiated various health programs to support diabetes management, which further enhances the opportunities for market expansion.
Moreover, these biosimilars facilitate cost-effective treatment alternatives, which essential in a nation where healthcare affordability is a priority. Consequently, both Type I and Type II Diabetes represent significant portions of the market, catering to a vast patient population requiring consistent and effective insulin therapies. As healthcare accessibility improves and awareness increases, the demand for biosimilars in these diabetes types is expected to increase, solidifying their importance in India's healthcare landscape.
The India Insulin Biosimilars Market has evolved significantly over the last decade, driven by the increasing prevalence of diabetes and the rising demand for affordable insulin therapies. As the healthcare landscape in India transforms, several players are emerging, focusing on developing biosimilars that mimic the efficacy and safety of original insulin formulations.
This burgeoning market has attracted both established pharmaceutical giants and new entrants, fostering a competitive environment characterized by innovation and strategic partnerships. Understanding the competitive dynamics, such as market positioning, product differentiation, and pricing strategies, is essential for stakeholders aiming to leverage growth opportunities in this thriving sector.Glenmark Pharmaceuticals has established a strong presence in the Indian Insulin Biosimilars Market, leveraging its robust R&D capabilities and commitment to affordable healthcare.
The company boasts a diverse portfolio of insulin biosimilars, aimed at addressing the growing needs of diabetic patients in India. Its focus on developing high-quality products that meet regulatory requirements assures healthcare providers and patients of safety and efficacy. Glenmark has strategically collaborated with various stakeholders in the healthcare ecosystem, enhancing its distribution channels while fostering awareness around diabetes management.
The company's dedication to stringent quality assurance processes and patient-centric approaches further solidifies its competitive edge in the market.Dr. Reddy's Laboratories is another formidable player in the Indian Insulin Biosimilars Market, having developed a suite of insulin biosimilars that cater specifically to the local population's needs. The company holds a commendable reputation for its commitment to innovation and patient access, evidenced by its well-received biosimilar products across various therapeutic categories.
Dr. Reddy's fosters a strong market presence influenced by strategic mergers and acquisitions, which have enhanced its research capabilities and operational efficiencies. The company actively engages in partnerships with healthcare providers, ensuring its products are readily available while reinforcing the importance of diabetes management among patients. Dr. Reddy's unwavering pursuit of quality and affordability positions it strongly in this competitive landscape, enabling it to contribute positively to the overall healthcare landscape in India.
Recent developments in the India Insulin Biosimilars Market reflect significant transformation and growth. The market is witnessing increased participation from several major companies, including Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, and Biocon, which have been advancing their pipelines to enhance access to affordable diabetes treatment. In June 2023, Biocon announced the launch of its insulin biosimilar in India, addressing the growing demand for insulin products in the country, which is home to over 77 million diabetics as per the International Diabetes Federation.
In September 2023, Dr. Reddy's Laboratories reported an expansion in its biosimilars portfolio, focusing on additional insulin products to capture market share. Furthermore, in May 2023, Zydus Cadila's expansion into the biosimilars space indicated a commitment toward innovation in diabetes management. Merger and acquisition activities have included Sun Pharmaceutical Industries' potential acquisition discussions with certain mid-size firms to bolster its biosimilars division. The overall market valuation of insulin biosimilars continues to grow significantly due to rising diabetic cases, resulting in increased investments and development efforts across prominent India-based pharmaceutical companies, enhancing competition and product availability.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 26.12(USD Million) |
| MARKET SIZE 2024 | 45.0(USD Million) |
| MARKET SIZE 2035 | 300.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.823% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Intas Pharmaceuticals, Zydus Cadila, Onco Therapies, Sandoz, Alkem Laboratories, Sun Pharmaceutical Industries, Mylan, Bharat Biotech, Hetero Labs, Wockhardt, Lupin, Biocon |
| SEGMENTS COVERED | Type, Indication |
| KEY MARKET OPPORTUNITIES | Increasing diabetes prevalence, Cost-effective treatment options, Rising healthcare expenditure, Supportive regulatory environment, Growing demand for affordable medications |
| KEY MARKET DYNAMICS | Increasing diabetes prevalence, Growing patient awareness, Expanding healthcare access, Cost-effectiveness of biosimilars, Strong pipeline of products |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The projected market size of the India Insulin Biosimilars Market in 2024 is estimated to be valued at 45.0 USD Million.
By 2035, the India Insulin Biosimilars Market is expected to reach an estimated value of 300.0 USD Million.
The expected CAGR for the India Insulin Biosimilars Market from 2025 to 2035 is 18.823%.
In 2035, the Long-acting biosimilars segment is projected to have the largest market value of 120.0 USD Million.
The market value of Rapid-acting biosimilars in 2024 is projected to be 15.0 USD Million.
Key players in the India Insulin Biosimilars Market include Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, and Intas Pharmaceuticals.
By 2035, the projected market value for Premixed biosimilars is expected to be 90.0 USD Million.
The expected fastest-growing type in the market from 2025 to 2035 is likely to be Long-acting biosimilars.
Anticipated challenges in the India Insulin Biosimilars Market include regulatory hurdles and competition from innovator products.
Current global economic conditions may influence supply chains and pricing strategies in the India Insulin Biosimilars Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
